➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKinsey
Dow
Merck
Johnson and Johnson

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

Ioversol - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for ioversol and what is the scope of freedom to operate?

Ioversol is the generic ingredient in five branded drugs marketed by Liebel-flarsheim and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for ioversol. One supplier is listed for this compound.

Summary for ioversol
Recent Clinical Trials for ioversol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 0
Instituto Mexicano del Seguro SocialPhase 3
MallinckrodtPhase 4

See all ioversol clinical trials

Pharmacology for ioversol

US Patents and Regulatory Information for ioversol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 019710-005 Jan 22, 1992 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 020923-003 May 28, 1998 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 160 ioversol INJECTABLE;INJECTION 019710-003 Dec 30, 1988 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 019710-004 Jan 22, 1992 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 020923-002 May 29, 1998 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ioversol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 019710-001 Dec 30, 1988 ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 160 ioversol INJECTABLE;INJECTION 019710-003 Dec 30, 1988 ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 020923-003 May 28, 1998 ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998 ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 019710-004 Jan 22, 1992 ⤷  Free Forever Trial ⤷  Free Forever Trial
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 020923-002 May 29, 1998 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKinsey
Dow
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.